Search

Your search keyword '"Mikami, K."' showing total 1,658 results
Start Over Author "Mikami, K."
1,658 results on '"Mikami, K."'

2. Selection of AVP-Shortage Patients as Candidates for Low-Dose Oral Desmopressin Administration

Author

Takeuchi T, Maki K, Okuno Y, Hattori-Kato M, and Mikami K

Subjects
avp, osmolality, desmopressin, urination, Diseases of the genitourinary system. Urology, RC870-923
Abstract

Takumi Takeuchi,1 Kazuki Maki,1 Yumiko Okuno,1 Mami Hattori-Kato,2 Koji Mikami1 1Department of Urology, Japan Organization of Occupational Health and Safety, Kanto Rosai Hospital, Nakahara-ku, Kawasaki, Japan; 2Department of Urology, Tokyo Teishin Hospital, Chiyoda-ku, Tokyo 102-8798, JapanCorrespondence: Takumi TakeuchiDepartment of Urology, Japan Organization of Occupational Health and Safety, Kanto Rosai Hospital, 1-1 Kizukisumiyoshi-Cho, Nakahara-ku, Kawasaki 211-8510, JapanEmail takeuchit@abelia.ocn.ne.jpObjective: We herein attempted to select male patients with an elevated nocturnal urinary frequency possibly due to a shortage of AVP. These patients may be good candidates for low-dose oral desmopressin administration.Patients and Methods: Serum and spot urine osmolality, electrolytes, serum creatinine, casual blood glucose, plasma brain natriuretic polypeptide (BNP), and plasma AVP were measured at the same time in 97 elderly male patients with urinary symptoms under free water drinking.Results: A binary plot of plasma AVP and serum osmolality indicated a region at which patients had relatively lower AVP considering higher serum osmolality. It was tentatively named the desmopressin region. Twenty out of 97 (20.6%) patients were in the desmopressin region. Daily urine output did not exceed 3 L in any patient. Urine osmolality was slightly lower in patients in the desmopressin region. No significant differences were observed in urine volume, urinary frequency, or urination questionnaire scores between both groups.Conclusion: AVP-shortage patients may be selected for treatment with oral desmopressin based on measurements of serum osmolality and plasma AVP.Keywords: AVP, osmolality, desmopressin, urination

Published
2021

5. Progress and Prospects of X-Ray Laser Research in QST

Author

Nishikino, M., Hasegawa, N., Ishino, M., Imazono, T., Sasaki, A., Mikami, K., Dinh, T. -H., Suemoto, T., Namba, S., Faenov, A. Ya., Pikuz, T. A., Ichimaru, S., Hatayama, M., Kawachi, T., Kawachi, Tetsuya, editor, Bulanov, Sergei V., editor, Daido, Hiroyuki, editor, and Kato, Yoshiaki, editor

Published
2018
Full Text
View/download PDF

7. CO2 Huff and Puff Injection Operation Overview in Jatibarang Field Lessons Learned from a Successful Case Study in Mature Oil Field

Author

Halinda, D., additional, Zariat, A. Az, additional, Muraza, O., additional, Marteighianti, M., additional, Setyawan, W., additional, Haribowo, A., additional, Rajab, M., additional, Firmansyah, M., additional, Hasan, I., additional, Nurlia, D., additional, Adham, A., additional, Prabowo, P., additional, Okabe, H., additional, Mikami, K., additional, Kento, K., additional, Susanta, P., additional, and Palupi, A. S., additional

Published
2023
Full Text
View/download PDF

10. Oct4B, CD90, and CD73 are upregulated in bladder tissue following electro-resection of the bladder

Author

Takeuchi T, Tonooka A, Okuno Y, Hattori-Kato M, and Mikami K

Subjects
Oct4B, CD90, CD73, Electric, Stimulation, Bladder, Medicine, Medicine (General), R5-920
Abstract

Aim: We tested the hypothesis that stimulation by electro-resection of bladder tissue induces stem cells in the tissue repair process. Materials & Methods: After primary transurethral resection of a bladder tumor and surrounding tissue (TUR-Bt), second TUR-Bt was performed. Tissues excised by second TUR-Bt were immunohistochemically stained for Oct4, a marker of pluripotency, and for CD90 and CD73, markers of mesenchymal stromal cells, when no bladder tumor cells remained. Results and Conclusions: Oct4B protein was sporadically stained in the cytoplasm of interstitial cells in four out of eight cases. CD90 and CD73 are upregulated in interstitial and vascular endothelial cells without CD45 expression. Mesenchymal stromal cells, but not pluripotent stem cells, may be mainly involved in bladder tissue repair.

Published
2016

11. Detection of AR-V7 mRNA in whole blood may not predict the effectiveness of novel endocrine drugs for castration-resistant prostate cancer

Author

Takeuchi T, Okuno Y, Hattori-Kato M, Zaitsu M, and Mikami K

Subjects
AR-V7, prostate cancer, castration-resistant, Diseases of the genitourinary system. Urology, RC870-923
Abstract

Takumi Takeuchi, Yumiko Okuno, Mami Hattori-Kato, Masayoshi Zaitsu, Koji MikamiDepartment of Urology, Kanto Rosai Hospital, Kawasaki, JapanAbstract: A splice variant of androgen receptor (AR), AR-V7, lacks in androgen-binding portion and leads to aggressive cancer characteristics. Reverse transcription-polymerase chain reactions (PCRs) and subsequent nested PCRs for the amplification of AR-V7 and prostate-specific antigen (PSA) transcripts were done for whole blood of patients with prostate cancer and male controls. With primary reverse transcription PCRs, AR-V7 and PSA were detected in 4.5% and 4.7% of prostate cancer, respectively. With nested PCRs, AR-V7 messenger RNA (mRNA) was positive in 43.8% of castration-sensitive prostate cancer and 48.1% of castration-resistant prostate cancer (CRPC), while PSA mRNA was positive in 6.3% of castration-sensitive prostate cancer and 18.5% of CRPC. Whole-blood samples of controls showed AR-V7 mRNA expression by nested PCR. Based on multivariate analysis, expression of AR-V7 mRNA in whole blood was not significantly correlated with clinical parameters and PSA mRNA in blood, while univariate analysis showed a correlation between AR-V7 mRNA and metastasis at initial diagnosis. Detection of AR-V7 mRNA did not predict the reduction of serum PSA in patients with CRPC following abiraterone and enzalutamide administration. In conclusion, AR-V7 mRNA expression in normal hematopoietic cells may have annihilated the manifestation of aggressiveness of prostate cancer and the prediction of the effectiveness of abiraterone and enzalutamide by the assessment of AR-V7 mRNA in blood.Keywords: AR-V7, prostate cancer, castration-resistant

Published
2016

13. Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer: a collaborative analysis of 20 prospective studies and Mendelian randomization analysis

Author

Watts, EL, Perez-Cornago, A, Fensom, GK, Smith-Byrne, K, Noor, U, Andrews, CD, Gunter, MJ, Holmes, M, Martin, RM, Tsilidis, KK, Albanes, D, Barricarte, A, Bueno-de-Mesquita, HB, Cohn, BA, Deschasaux-Tanguy, M, Dimou, NL, Ferrucci, L, Flicker, L, Freedman, ND, Giles, GG, Giovannucci, EL, Haiman, CA, Hankey, GJ, Holly, JMP, Huang, J, Huang, W-Y, Hurwitz, LM, Kaaks, R, Kubo, T, Le Marchand, L, MacInnis, RJ, Mannisto, S, Metter, EJ, Mikami, K, Mucci, LA, Olsen, AW, Ozasa, K, Palli, D, Penney, KL, Platz, EA, Pollak, MN, Roobol, MJ, Schaefer, CA, Schenk, JM, Stattin, P, Tamakoshi, A, Thysell, E, Tsai, CJ, Touvier, M, Van Den Eeden, SK, Weiderpass, E, Weinstein, SJ, Wilkens, LR, Yeap, BB, Allen, NE, Key, TJ, Travis, RC, Watts, EL, Perez-Cornago, A, Fensom, GK, Smith-Byrne, K, Noor, U, Andrews, CD, Gunter, MJ, Holmes, M, Martin, RM, Tsilidis, KK, Albanes, D, Barricarte, A, Bueno-de-Mesquita, HB, Cohn, BA, Deschasaux-Tanguy, M, Dimou, NL, Ferrucci, L, Flicker, L, Freedman, ND, Giles, GG, Giovannucci, EL, Haiman, CA, Hankey, GJ, Holly, JMP, Huang, J, Huang, W-Y, Hurwitz, LM, Kaaks, R, Kubo, T, Le Marchand, L, MacInnis, RJ, Mannisto, S, Metter, EJ, Mikami, K, Mucci, LA, Olsen, AW, Ozasa, K, Palli, D, Penney, KL, Platz, EA, Pollak, MN, Roobol, MJ, Schaefer, CA, Schenk, JM, Stattin, P, Tamakoshi, A, Thysell, E, Tsai, CJ, Touvier, M, Van Den Eeden, SK, Weiderpass, E, Weinstein, SJ, Wilkens, LR, Yeap, BB, Allen, NE, Key, TJ, and Travis, RC

Abstract

BACKGROUND: Previous studies had limited power to assess the associations of circulating insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs) with clinically relevant prostate cancer as a primary endpoint, and the association of genetically predicted IGF-I with aggressive prostate cancer is not known. We aimed to investigate the associations of IGF-I, IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3 concentrations with overall, aggressive and early-onset prostate cancer. METHODS: Prospective analysis of biomarkers using the Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group dataset (up to 20 studies, 17 009 prostate cancer cases, including 2332 aggressive cases). Odds ratios (OR) and 95% confidence intervals (CI) for prostate cancer were estimated using conditional logistic regression. For IGF-I, two-sample Mendelian randomization (MR) analysis was undertaken using instruments identified using UK Biobank (158 444 men) and outcome data from PRACTICAL (up to 85 554 cases, including 15 167 aggressive cases). Additionally, we used colocalization to rule out confounding by linkage disequilibrium. RESULTS: In observational analyses, IGF-I was positively associated with risks of overall (OR per 1 SD = 1.09: 95% CI 1.07, 1.11), aggressive (1.09: 1.03, 1.16) and possibly early-onset disease (1.11: 1.00, 1.24); associations were similar in MR analyses (OR per 1 SD = 1.07: 1.00, 1.15; 1.10: 1.01, 1.20; and 1.13; 0.98, 1.30, respectively). Colocalization also indicated a shared signal for IGF-I and prostate cancer (PP4: 99%). Men with higher IGF-II (1.06: 1.02, 1.11) and IGFBP-3 (1.08: 1.04, 1.11) had higher risks of overall prostate cancer, whereas higher IGFBP-1 was associated with a lower risk (0.95: 0.91, 0.99); these associations were attenuated following adjustment for IGF-I. CONCLUSIONS: These findings support the role of IGF-I in the development of prostate cancer, including for aggressive disease.

Published
2022

14. Circulating free testosterone and risk of aggressive prostate cancer: Prospective and Mendelian randomisation analyses in international consortia

Author

Watts, EL, Perez-Cornago, A, Fensom, GK, Smith-Byrne, K, Noor, U, Andrews, CD, Gunter, MJ, Holmes, M, Martin, RM, Tsilidis, KK, Albanes, D, Barricarte, A, Bueno-de-Mesquita, B, Chen, C, Cohn, BA, Dimou, NL, Ferrucci, L, Flicker, L, Freedman, ND, Giles, GG, Giovannucci, EL, Goodman, GE, Haiman, CA, Hankey, GJ, Huang, J, Huang, W-Y, Hurwitz, LM, Kaaks, R, Knekt, P, Kubo, T, Langseth, H, Laughlin, G, Le Marchand, L, Luostarinen, T, MacInnis, RJ, Maenpaa, HO, Mannisto, S, Metter, JE, Mikami, K, Mucci, LA, Olsen, AW, Ozasa, K, Palli, D, Penney, KL, Platz, EA, Rissanen, H, Sawada, N, Schenk, JM, Stattin, P, Tamakoshi, A, Thysell, E, Tsai, CJ, Tsugane, S, Vatten, L, Weiderpass, E, Weinstein, SJ, Wilkens, LR, Yeap, BB, Allen, NE, Key, TJ, Travis, RC, Watts, EL, Perez-Cornago, A, Fensom, GK, Smith-Byrne, K, Noor, U, Andrews, CD, Gunter, MJ, Holmes, M, Martin, RM, Tsilidis, KK, Albanes, D, Barricarte, A, Bueno-de-Mesquita, B, Chen, C, Cohn, BA, Dimou, NL, Ferrucci, L, Flicker, L, Freedman, ND, Giles, GG, Giovannucci, EL, Goodman, GE, Haiman, CA, Hankey, GJ, Huang, J, Huang, W-Y, Hurwitz, LM, Kaaks, R, Knekt, P, Kubo, T, Langseth, H, Laughlin, G, Le Marchand, L, Luostarinen, T, MacInnis, RJ, Maenpaa, HO, Mannisto, S, Metter, JE, Mikami, K, Mucci, LA, Olsen, AW, Ozasa, K, Palli, D, Penney, KL, Platz, EA, Rissanen, H, Sawada, N, Schenk, JM, Stattin, P, Tamakoshi, A, Thysell, E, Tsai, CJ, Tsugane, S, Vatten, L, Weiderpass, E, Weinstein, SJ, Wilkens, LR, Yeap, BB, Allen, NE, Key, TJ, and Travis, RC

Abstract

Previous studies had limited power to assess the associations of testosterone with aggressive disease as a primary endpoint. Further, the association of genetically predicted testosterone with aggressive disease is not known. We investigated the associations of calculated free and measured total testosterone and sex hormone-binding globulin (SHBG) with aggressive, overall and early-onset prostate cancer. In blood-based analyses, odds ratios (OR) and 95% confidence intervals (CI) for prostate cancer were estimated using conditional logistic regression from prospective analysis of biomarker concentrations in the Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group (up to 25 studies, 14 944 cases and 36 752 controls, including 1870 aggressive prostate cancers). In Mendelian randomisation (MR) analyses, using instruments identified using UK Biobank (up to 194 453 men) and outcome data from PRACTICAL (up to 79 148 cases and 61 106 controls, including 15 167 aggressive cancers), ORs were estimated using the inverse-variance weighted method. Free testosterone was associated with aggressive disease in MR analyses (OR per 1 SD = 1.23, 95% CI = 1.08-1.40). In blood-based analyses there was no association with aggressive disease overall, but there was heterogeneity by age at blood collection (OR for men aged <60 years 1.14, CI = 1.02-1.28; Phet = .0003: inverse association for older ages). Associations for free testosterone were positive for overall prostate cancer (MR: 1.20, 1.08-1.34; blood-based: 1.03, 1.01-1.05) and early-onset prostate cancer (MR: 1.37, 1.09-1.73; blood-based: 1.08, 0.98-1.19). SHBG and total testosterone were inversely associated with overall prostate cancer in blood-based analyses, with null associations in MR analysis. Our results support free testosterone, rather than total testosterone, in the development of prostate cancer, including aggressive subgroups.

Published
2022

23. Efficacy and safety of abiraterone acetate plus prednisolone in patients with early metastatic castration-resistant prostate cancer who failed first-line androgen-deprivation therapy: a single-arm, phase 4 study

Author

Kobayashi, K, primary, Okuno, N, additional, Arai, G, additional, Nakatsu, H, additional, Maniwa, A, additional, Kamiya, N, additional, Satoh, T, additional, Kikukawa, H, additional, Nasu, Y, additional, Uemura, H, additional, Nakashima, T, additional, Mikami, K, additional, Iinuma, M, additional, Tanabe, K, additional, Furukawa, J, additional, and Kobayashi, H, additional

Published
2020
Full Text
View/download PDF

27. Missing Reactivity of Trimethylsilyl Reagents: Dehalogenative Activation Enabling One-Pot Generation of Aryne from 2-Iodophenol

Author

Hirano T, Hitoshi H, and Mikami K

Subjects
chemistry.chemical_compound, Trimethylsilyl, chemistry, Reagent, 2-iodophenol, Halogen, Substrate (chemistry), Reactivity (chemistry), Combinatorial chemistry, Aryne, Carbanion
Abstract

Herein we present a missing reactivity of trimethylsilyl reagents; dehalogenative activation, which involves abstracting a halogen atom and anionically activating the substrate similar to the halogen-metal exchange reaction in classical carbanion species. This missing reactivity allowed for the one-pot generation of aryne from 2-iodophenol.

Published
2019

28. The associations of anthropometric, behavioural and sociodemographic factors with circulating concentrations of IGF‐I, IGF‐II, IGFBP‐1, IGFBP‐2 and IGFBP‐3 in a pooled analysis of 16,024 men from 22 studies

Author

Watts, EL, Perez-Cornago, A, Appleby, PN, Albanes, D, Ardanaz, E, Black, A, Bueno-De-Mesquita, HB, Chan, JM, Chen, C, Chubb, SAP, Cook, MB, Deschasaux, M, Donovan, JL, English, DR, Flicker, L, Freedman, ND, Galan, P, Giles, GG, Giovannucci, EL, Gunter, MJ, Habel, LA, Häggström, C, Haiman, C, Hamdy, FC, Hercberg, S, Holly, JM, Huang, J, Huang, W-Y, Johansson, M, Kaaks, R, Kubo, T, Lane, JA, Layne, TM, Le Marchand, L, Martin, RM, Metter, EJ, Mikami, K, Milne, RL, Morris, HA, Mucci, LA, Neal, DE, Neuhouser, ML, Oliver, SE, Overvad, K, Ozasa, K, Pala, V, Pernar, CH, Pollak, M, Rowlands, M-A, Schaefer, CA, Schenk, JM, Stattin, P, Tamakoshi, A, Thysell, E, Touvier, M, Trichopoulou, A, Tsilidis, KK, Van Den Eeden, SK, Weinstein, SJ, Wilkens, L, Yeap, BB, Key, TJ, Allen, NE, Travis, RC, Nuffield Department of Population Health [Oxford], University of Oxford [Oxford], National Cancer Institute [Bethesda] (NCI-NIH), National Institutes of Health [Bethesda] (NIH), Public Health Institute of Navarra, National Institute for Public Health and the Environment [Bilthoven] (RIVM), University of California [San Francisco] (UCSF), University of California, Fred Hutchinson Cancer Research Center [Seattle] (FHCRC), The University of Western Australia (UWA), Equipe 3: EREN- Equipe de Recherche en Epidémiologie Nutritionnelle (CRESS - U1153), Institut National de la Recherche Agronomique (INRA)-Conservatoire National des Arts et Métiers [CNAM] (CNAM)-Université Paris 13 (UP13)-Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), University of Bristol [Bristol], Melbourne School of Population and Global Health [Melbourne], University of Melbourne, Harvard T.H. Chan School of Public Health, Harvard Medical School [Boston] (HMS), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Kaiser Permanente, Umeå University, Keck School of Medicine [Los Angeles], University of Southern California (USC), Nuffield (Nuffield), German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), University of Occupational and Environmental Health [Kitakyushu] (UEOH), Icahn School of Medicine at Mount Sinai [New York] (MSSM), University of Hawai'i [Honolulu] (UH), The University of Tennessee Health Science Center [Memphis] (UTHSC), Japanese Red Cross Kyoto Daiichi Hospital, SA Pathology [Adelaide, SA, Australia], University of York [York, UK], Aarhus University [Aarhus], Radiation Effects Research Foundation, Fondazione IRCCS Istituto Nazionale Tumori - National Cancer Institute [Milan], McGill University = Université McGill [Montréal, Canada], Uppsala Universitet [Uppsala], Hokkaido University [Sapporo, Japan], Hellenic Health Foundation, Imperial College London, University of Ioannina, Deschasaux-Tanguy, Mélanie, University of Oxford, University of California [San Francisco] (UC San Francisco), University of California (UC), Université Paris 13 (UP13)-Institut National de la Recherche Agronomique (INRA)-Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), and Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Male, Aging, Neoplasms, 80 and over, Prospective Studies, Insulin-Like Growth Factor I, POPULATION, Cancer, Aged, 80 and over, INSULIN-RESISTANCE, Tumor, Anthropometry, CARDIOVASCULAR RISK, SERUM-LEVELS, Middle Aged, Insulin-Like Growth Factor Binding Proteins, Oncology, Centre for Surgical Research, IGFBPs, ICEP, pooled analysis, Life Sciences & Biomedicine, Cancer Epidemiology, hormones, hormone substitutes, and hormone antagonists, Adult, Urologic Diseases, FACTOR-BINDING-PROTEIN, PROSTATE-CANCER RISK, Oncology and Carcinogenesis, and over, Young Adult, HORMONE, Insulin-Like Growth Factor II, GROWTH-FACTOR-I, Biomarkers, Tumor, Humans, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, METAANALYSIS, Aged, IGFs, Cancer och onkologi, Science & Technology, correlates, BODY-MASS INDEX, [SDV.AEN] Life Sciences [q-bio]/Food and Nutrition, Cross-Sectional Studies, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Cancer and Oncology, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition, Biomarkers
Abstract

Insulin‐like growth factors (IGFs) and insulin‐like growth factor binding proteins (IGFBPs) have been implicated in the aetiology of several cancers. To better understand whether anthropometric, behavioural and sociodemographic factors may play a role in cancer risk via IGF signalling, we examined the cross‐sectional associations of these exposures with circulating concentrations of IGFs (IGF‐I and IGF‐II) and IGFBPs (IGFBP‐1, IGFBP‐2 and IGFBP‐3). The Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group dataset includes individual participant data from 16,024 male controls (i.e. without prostate cancer) aged 22–89 years from 22 prospective studies. Geometric means of protein concentrations were estimated using analysis of variance, adjusted for relevant covariates. Older age was associated with higher concentrations of IGFBP‐1 and IGFBP‐2 and lower concentrations of IGF‐I, IGF‐II and IGFBP‐3. Higher body mass index was associated with lower concentrations of IGFBP‐1 and IGFBP‐2. Taller height was associated with higher concentrations of IGF‐I and IGFBP‐3 and lower concentrations of IGFBP‐1. Smokers had higher concentrations of IGFBP‐1 and IGFBP‐2 and lower concentrations of IGFBP‐3 than nonsmokers. Higher alcohol consumption was associated with higher concentrations of IGF‐II and lower concentrations of IGF‐I and IGFBP‐2. African Americans had lower concentrations of IGF‐II, IGFBP‐1, IGFBP‐2 and IGFBP‐3 and Hispanics had lower IGF‐I, IGF‐II and IGFBP‐3 than non‐Hispanic whites. These findings indicate that a range of anthropometric, behavioural and sociodemographic factors are associated with circulating concentrations of IGFs and IGFBPs in men, which will lead to a greater understanding of the mechanisms through which these factors influence cancer risk., What's new? In many cancers, evidence points to insulin‐like growth factors and their associated binding proteins as a possible culprit. This study investigated how IGF and IGF binding proteins correlate with various other cancer‐associated factors. The authors obtained data from 16,000 cancer‐free males ranging in age from 22 to 89 years. Their analysis confirmed associations between circulating IGFs and IGFBPs and age, race/ethnicity and BMI. They also uncovered some new associations, including with height, drinking alcohol and smoking. IGFs and their binding proteins, they suggest, may be part of the mechanism by which these factors influence cancer risk.

Published
2019

40. Synthesis

Author

Mikami, K., primary, Matsumoto, Y., additional, and Shiono, T., additional

Published
2003
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results